CHANGSHENG BIO-TECHNOLOGY CO LTD |
End-of-day quote
Other stock markets
|
||
| - CNY | - |
|
| Sales 2016 | 1.02B 141M 11.04B | Sales 2017 | 1.55B 215M 16.84B | Capitalization | 14B 1.93B 152B |
|---|---|---|---|---|---|
| Net income 2016 | 425M 58.69M 4.61B | Net income 2017 | 566M 78.16M 6.14B | EV / Sales 2016 | 14.2 x |
| Net cash position 2016 | 2.36B 326M 25.58B | Net cash position 2017 | 2.31B 320M 25.1B | EV / Sales 2017 | 7.52 x |
| P/E ratio 2016 |
39.5
x | P/E ratio 2017 |
24.7
x | Employees | - |
| Yield 2016 |
1.73% | Yield 2017 |
2.78% | Free-Float | 31.27% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Quan Lu
CEO | Chief Executive Officer | 45 | 20/05/21 |
Chi Wu Chen
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/12/08 |
Xiang Ming Wang
BRD | Director/Board Member | 52 | 31/12/93 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ji Ti Liu
BRD | Director/Board Member | 68 | 31/12/09 |
Xiang Ming Wang
BRD | Director/Board Member | 52 | 31/12/93 |
Hong Quan Lu
CEO | Chief Executive Officer | 45 | 20/05/21 |
Changsheng Bio-technology Co., Ltd., formerly Lianyungang Huanghai Machinery Co., Ltd., is a China-based company principally engaged in the research, development, production and sale of human vaccine products. The Company's main products include live attenuated freeze-dried varicella vaccine, freeze-dried human rabies vaccine (Vero cells), freeze-dried live attenuated hepatitis A vaccine, influenza lysis vaccine, adsorption of cell-free diphtheria combined vaccine and ACYW Group 135 meningococcal polysaccharide vaccine. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 106M | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| -13.07% | 32.75B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B |
- Stock Market
- Equities
- 002680 Stock
